About: Therapeutic dilemma in the repression of severe acute respiratory syndrome coronavirus‐2 proteome

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Therapeutic dilemma in the repression of severe acute respiratory syndrome coronavirus‐2 proteome Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Therapeutic dilemma in the repression of severe acute respiratory syndrome coronavirus‐2 proteome
Creator	Asim, Muhammad Sadia, Aatika Basra, Raza
source	Medline; PMC
abstract	Currently, the pandemic coronavirus disease 2019 (COVID‐19) has unprecedentedly captivated its human hosts by causing respiratory illnesses because of evolution of the genetic makeup of novel coronavirus (CoV) known as severe acute respiratory syndrome coronavirus‐2 (SARS CoV‐2). As much as the researchers are inundated for the quest of effective treatments from available drugs, the discovery and trials of new experimental drugs are also at a threshold for clinical trials. There has been much concern regarding the new and targeted drugs considering the comprehensive ambiguity regarding the mechanism and pathway of the drug action with respect to the new and unpredictable structural and nonstructural proteins (NSPs) of SARS CoV‐2. This study was aimed to discuss functional pathways related to NSPs in CoVs with updated knowledge regarding SARS CoV‐2, mechanisms of action of certain approved and investigational drugs for correct orientation regarding the treatment strategies, including nucleotide analog mechanism, receptor analog mechanism, and peptide–peptide interactions, along with the impact of COVID‐19 on a global scale. Although there is a dire need for targeted drugs against SARS CoV‐2, the practical achievement of its cure is possible by only using effective drugs with appropriate mechanisms to eliminate the disease.
has issue date	2020-07-13(xsd:dateTime)
bibo:doi	10.1002/ddr.21710
bibo:pmid	32662099
has license	no-cc
sha1sum (hex)	03f1852ee8e15b9bd3c477d12c2cd8ebebb76723
schema:url	https://doi.org/10.1002/ddr.21710
resource representing a document's title	Therapeutic dilemma in the repression of severe acute respiratory syndrome coronavirus‐2 proteome
has PubMed Central identifier	PMC7405494
has PubMed identifier	32662099
schema:publication	Drug Dev Res
resource representing a document's body	covid:03f1852ee8e15b9bd3c477d12c2cd8ebebb76723#body_text
is schema:about of	named entity 'AVAILABLE DRUGS' named entity 'DRUGS' named entity 'HOSTS' named entity 'NEW' named entity 'genetic makeup' named entity 'COVID' named entity 'evolution' named entity 'drug action' named entity 'methylation' named entity 'polypeptide' named entity 'double-stranded RNA' named entity 'reproductive number' named entity 'ethanol' named entity 'RNA' named entity 'Shang' named entity 'cough' named entity 'phylogenetic analyses' named entity 'China' named entity 'viral pathogenesis' named entity 'transmission rate' named entity 'flatten the curve' named entity 'RNA polymerase' named entity 'hexameric' named entity 'ORFs' named entity 'catalyzes' named entity 'ribose' named entity 'Decroly' named entity 'protein' named entity 'homology' named entity 'viroid' named entity 'clinical investigation' named entity 'monocyte chemoattractant protein-1' named entity 'WHO' named entity 'nucleotide analog' named entity 'COVID' named entity 'virus replication' named entity 'case fatality rate' named entity 'COVID' named entity 'Chloroquine' named entity 'MCP-1' named entity 'cytokine storm' named entity 'SARS' named entity 'RNA' named entity 'NF-κB' named entity 'SARS CoV' named entity 'drug resistance' named entity 'IL-1β' named entity 'SARS CoV' named entity 'RNA genome' named entity 'ORFs' named entity 'SARS CoV' named entity 'nucleocapsid' named entity 'underdeveloped countries' named entity 'nucleocapsid' named entity 'social distancing' named entity 'interferon γ' named entity 'RNA' named entity 'RNA-dependent RNA polymerase' named entity 'protein' named entity 'losartan' named entity 'ORFs' named entity 'fatigue' named entity 'RNA replication' named entity 'RNA' named entity 'genome' named entity 'neutralizing antibodies' named entity 'IFN-γ' named entity 'SARS CoV' named entity 'T-cells' named entity 'replicases' named entity 'manganese' named entity 'N-terminal' named entity 'drug target' named entity 'viroid' named entity 'transferase' named entity 'angiotensin converting enzyme' named entity 'positive reinforcement' named entity 'RDRP' named entity 'underdeveloped countries'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software